Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114255 | 0.81 | — | — | |
| SCHEMBL20636979 | 0.79 | — | — | |
| SCHEMBL19606552 | 0.77 | — | — | |
| SCHEMBL8379654 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNASLC15A2TDP1 | |
| SCHEMBL5577365 | 0.74 | ALDH1A1 (0.43) | ALDH1A1LMNASLC15A2TDP1ACHE | |
| SCHEMBL10993375 | 0.74 | ALDH1A1 (0.38) | ALDH1A1LMNASLC15A2 | |
| SCHEMBL126775 | 0.73 | ALDH1A1 (0.56) | ALDH1A1LMNASLC15A2TDP1ACHE | |
| SCHEMBL20378893 | 0.72 | ALDH1A1 (0.36) | ALDH1A1LMNASLC15A2TDP1 | |
| SCHEMBL20524894 | 0.72 | ALDH1A1 (0.36) | ALDH1A1LMNASLC15A2TDP1 | |
| SCHEMBL11814795 | 0.71 | ALDH1A1 (0.35) | ALDH1A1LMNASLC15A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040242530-A1 | Orthoester protecting groups | DHARMACON, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-6590093-B1 | Modified RNA which can be easily handled and analyzed with minimal degradation; stability; can use in synthesis of polymers containing RNA nucleotides | DHARMACON, INC. | 2003-07-08 | — | — | US | disclosed |
| US-6111086-A | BLOCKING AGENTS FOR 2'-O POSITION DURING RNA SYNTHESIS; CLEAVABLE UNDER MILD ACIDIC CONDITIONS LEAVING QUALITY RNA | DHARMACON, INC. | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242530-A1 | Orthoester protecting groups | NSUN2, RNGTT, NOP2 | ALDH1A1 1506/4885LMNA 1587/4885SLC15A2 4610/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | ALDH1A1 1923/4885LMNA 111/4885SLC15A2 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.